Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Y mAbs Therapeutics (YMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Y mAbs Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.70 +0.37    +2.27%
29/02 - Closed. Currency in USD ( Disclaimer )
After Hours
21.38
+4.68
+28.02%
0:30:13 - Real-time Data
  • Volume: 310,052
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.44 - 17.02
Type:  Equity
Market:  United States
Y mAbs Therapeutics 16.70 +0.37 +2.27%

Y mAbs Therapeutics Company Profile

 
Read the Y mAbs Therapeutics company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

148

Equity Type

ORD

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody-based therapeutic cancer products. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS (omburtamab), which targets tumors that express B7-H3. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb) that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. Omburtamab is a novel murine monoclonal antibody designed for compartmental immunotherapy. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several types of cancers, including pediatric CNS/LM from NB.

Contact Information

Address 230 Park Avenue Suite 3350
New York, 10169
United States
Phone 646 885 8505
Fax -

Top Executives

Name Age Since Title
James Irvin Healy 57 2017 Independent Chairman of the Board
Johan Ernst Wedell-Wedellsborg 53 2015 Independent Director
Thomas Gad 53 2015 Founder, Chief Business Officer & Vice Chairman
Gérard Ber 65 2018 Independent Director
Laura Jean Hamill 58 2020 Independent Director
Michael Rossi 52 2023 CEO, President & Director
Ashutosh Tyagi 46 2017 Independent Director
David N. Gill 68 2017 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

YMAB Comments

Write your thoughts about Y mAbs Therapeutics
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email